Last updated: February 15, 2026
Key Insights for Biopharmaceutical Patents in Morocco
What Are the Patentability Criteria?
Morocco’s patent law aligns with international standards. To qualify, biopharmaceutical inventions must meet novelty, inventive step, and industrial applicability:
- Novelty: The invention cannot be disclosed publicly before the filing date. Public disclosures include publications, presentations, or existing patents in Morocco or abroad.
- Inventive Step: The invention must not be obvious to a person skilled in the field based on prior art.
- Industrial Applicability: The invention must have a practical application in industry or medicine.
Biopharmaceutical inventions must also comply with Moroccan law excluding certain subject matter from patentability, notably:
- Certain methods of treatment or surgery, unless specifically related to medical devices.
- Natural substances or compounds existing in nature unless significantly modified (e.g., isolated DNA or proteins with new properties).
- Plants and animals, unless biotechnological inventions involving microorganisms or genetically modified organisms are involved.
How Enforceability Is Established
Enforceability depends on:
- Patent Granting: The patent must be granted by the Moroccan Office of Industrial and Commercial Property (OMPIC). The process involves filing, examination, and publication.
- Claims Clarity and Support: Patent claims must be clear, concise, and fully supported by the description. Vagueness or ambiguity can weaken enforceability.
- Prior Art Search: Patent enforceability can be challenged during litigation if prior art or obviousness is established, undermining patent rights.
What Is the Scope of Claims Usually Allowed?
Moroccan patents in the biopharmaceutical sector adhere to the following scope restrictions:
- Claim Breadth: Claims should be sufficiently broad to cover the core invention but not so broad as to encompass prior art or naturally occurring substances.
- Product vs. Process Claims: Products such as novel proteins or drugs are claimable directly. Processes for manufacturing these products can be claimed as well.
- Use Claims: Claims covering specific therapeutic uses of compounds are generally allowed, provided they are clearly defined.
- Swiss-Style Claims: These are often used for new medical uses, describing the application of a known compound for a new indication.
Specific Considerations for Biopharmaceutical Patents
- Sequence Listings: Patents encompassing nucleic acids or amino acid sequences require detailed sequence listings complying with WIPO standards, which are accepted in Morocco.
- Data and Disclosure: Sufficient experimental data must support the claims, particularly for second medical uses or biological material inventions.
- Patent Term: The standard duration is 20 years from the filing date, with possible extensions for products subject to regulatory delays.
Comparative Analysis with International Practice
| Criterion |
Morocco |
EU/US |
| Patent Subject Matter |
Similar exclusions; natural substances generally not patentable unless significantly modified |
Similar; natural substances often not patentable unless structurally modified or isolated |
| Patent Term |
20 years |
20 years |
| Data Requirements |
Must support claims; biological inventions need detailed disclosure |
Similar; increased emphasis on inventive step in biotech |
| Claims Scope |
Must balance breadth and support |
Similar; use of Swiss claims common |
Challenges Specific to the Moroccan Patent System
- Examination Approach: Morocco does not conduct substantive examination before grant; formalities are checked, making prior art searches and oppositions limited.
- Opposition and Enforcement: Limited mechanisms for opposition. Enforcement primarily occurs through civil litigation, which can be lengthier due to procedural system characteristics.
- Biotechnology Focus: No specific guidelines distinct from general patent rules. Patent examiners apply generic standards, which may differ from regions with biotech-specific examination procedures.
Summary
Biopharmaceutical patents in Morocco require detailed disclosure, clear claim drafting, and a focus on inventive step and novelty. The scope is constrained by natural substance exclusions and the need for strong support. Enforceability depends on adherence to formal requirements and legal procedures, with limited substantive examination.
Key Takeaways
- Patentability hinges on novelty, inventive step, and industrial application, with specific exclusions for natural substances and surgical methods.
- Enforceability depends on patent grant clarity and legal procedures, with formal examination processes limiting prior art analysis.
- Claims should balance breadth with support, covering products, processes, and new uses, often using Swiss-style claims for medical indications.
- Biological inventions require detailed sequence disclosures, and data must substantiate claims.
- Enforcement relies on civil litigation; opposition mechanisms are limited within Morocco’s patent system.
FAQs
1. Can naturally occurring substances be patented in Morocco?
Only if the substances are isolated and substantially modified, resulting in new, industrially applicable properties. Raw natural substances are generally not patentable.
2. Are methods of medical treatment patentable?
Methods of surgical or therapeutic treatment are typically excluded. Patentability extends to devices and specific biotechnological processes related to treatment.
3. Does Morocco recognize utility extensions or patent term adjustments?
Standard 20-year patent term applies; extensions are not explicitly provided, but delays due to regulatory approval can extend effective market exclusivity.
4. How detailed must sequence disclosures be?
They should comply with WIPO standards, providing full sequence listings, accession numbers, and sufficient biological data to support inventive claims.
5. Are second medical use claims enforceable in Morocco?
Yes, as long as claims are clearly defined and supported by experimental data, and they specify the new therapeutic application distinctly.
Sources
- Moroccan Patent Law, Law No. 17-97, 1997.
- Moroccan Office of Industrial and Commercial Property (OMPIC) guidelines.
- WIPO Standard Sequence Listings.
- European Patent Convention (EPC) and United States Patent Law for comparative analysis.
